Cancer Bio-Immunotherapy in Siena - XIth NIBIT Meeting

Siena - October 17-19, 2013

Scientific Committee: NIBIT Board of Directors

Thursday, October 17

12:00     Arrival/Registration/Light lunch

14:00     Welcome addresses

**Session 1:**  Revisiting tumor associated mutated antigens
*Chairs:* Giorgio Parmiani (Milan, IT) and Zlatko Trajanoski (Innsbruck, AT)

14:15     Zlatko Trajanoski (Innsbruck, AT): “The colorectal cancer antigenome: what can we learn from next-generation sequencing data”

14:40     Ugur Sahin (Mainz, DE): “Genomics tailored cancer immunotherapy: towards bedside”

15:05     Paolo Dellabona (Milan, IT): “Immunogenicity of mutated antigens of colorectal cancer”

15:30     Danila Valmori (Nantes, FR) “Tumors antigen-specific CD4 T effector and regulatory subsets in human cancer: implications for the developments of vaccines”

16:00     Coffee break

**Session 2:**  Cancer stem cells and immune cells crosstalk at the metastasis forefront
*Chairs:* Mario P. Colombo (Milan, IT) and Ruggero De Maria (Rome, IT)
16:40 Ilaria Malanchi (London, GB): “Putting cancer stem cells in context”

17:05 Ruggero De Maria (Rome, IT): “Therapeutic targeting of cancer stem cells”

17:30 Cristina Maccalli (Milan, IT): “Immune profile of cancer stem cells of human solid tumors”

Abstracts selected for oral presentation

17:55 Elena Jachetti (Milan, IT): “Tenascin-C protects early-disseminated cancer stem cells from immune surveillance by arresting T-cell activation”

18:10 Pier Adelchi Ruffini (Siena, IT): “Targeting cancer stem cells in breast cancer through CXCR1: overview of a development plan and preliminary results”

19:30 Wine and Cheese

21:00 General Assembly of the NIBIT

Friday, October 18

Session 3: Metabolism at the interface between immune and cancer cells

Chairs: Vincenzo Bronte (Verona, IT) and Barbara Seliger (Halle, DE)

8:30 Matteo Bellone (Milan, IT): “Cancer metabolism and fitness of tumor infiltrating lymphocytes”


9:20 Vincenzo Bronte (Verona, IT): “Cancer metabolism and immune suppression”

09:45 Barbara Seliger (Halle, DE): “Dual role of MicroRNAs on tumors by shaping immune surveillance and growth properties”
Abstracts selected for oral presentation

10:10 Raffaella Fontana (Milan, IT): “Identification of Trem-1 as a novel target of nuclear receptor ligands in dendritic cells”

10:25 Franco M. Venanzi (Camerino, IT): “At the cross road of autophagy and cancer: a signaling “Hub” protein p62 (SQSTM-1) as target for cancer immunotherapy”

10:40 Coffee break

Session 4: Adoptive immunotherapy

Chairs: Vincenzo Russo (Milan, IT) and Alberto Amadori (Padua, IT)

11:10 Robert Hawkins (Manchester, GB): “Adoptive cell therapy with natural and engineered T- cells”

11:35 Gianpietro Dotti (Houston, USA): “Adoptive immunotherapy with CAR-modified T cells”

12:00 Attilio Bondanza (Milan, IT): “Overcoming the toxicity hurdles of adoptive T-cell therapy”

Abstracts selected for oral presentation

12:25 Dario Sangiolo (Turin, IT): “Cytokine-Induced Killer (CIK) cells effectively kill autologous putative cancer stem cells in bone and soft tissue sarcomas.”

12:40 Federica Moschella (Rome, IT): “Cyclophosphamide promotes a type I interferon-associated sterile inflammation in cancer patients’ PBMC: relevance for the combination of chemotherapy and adoptive immunotherapy”

12:55 MedImmune and NIBIT Foundation Luncheon Satellite Symposium: Current and innovative treatment for malignant mesothelioma

Chairs: Michele Maio (Siena, IT) and Ramy Ibrahim (Gaithersburg, USA)

Luciano Mutti (Vercelli, IT): “Up-dates on the biology”
Giovanni Ceresoli (Bergamo, IT): “Current medical therapy”

Luana Calabrò (Siena, IT): “Anti-CTLA4 treatment”

Session 5: **Immunomodulating antibodies in melanoma and beyond**  
*Chairs:* Michele Maio (Siena, IT) and Mario Sznol (New Heaven, USA)

14:30 Jeffrey Weber (Tampa, USA): “Overview on immune checkpoint for cancer treatment”

14:55 Mario Sznol (New Heaven, USA): “Immunotherapy with anti-PD1 and combinations”

15:20 To be announced: “PDL-1 in melanoma and beyond”


16:10 Cosimo Paga (Rome, IT): “From chemotherapy to immunotherapy: clinical and regulatory challenges”

**Abstracts selected for oral presentation**

16:35 Dalil Hannani (Villejuif, FR): “IL-2 dependent efficacy of anti-CTLA4 antibody: identification of a negative predictive marker of response to Ipilimumab”

16:50 Alessia Covre (Siena, IT): “DNA hypomethylation improves the anti-tumor activity of CTLA-4 immune blockade in a syngeneic mouse model”

17:05 Tea Break

Session 6: **Non-profit clinical trials ongoing in Italy**  
*Chairs:* Ruggero Ridolfi (Meldola, IT) and Pier Francesco Ferrucci (Milan, IT)

17:35 Anna Maria Di Giacomo (Siena, IT): “NIBIT-M2”

Giorgio Parmiani (Milan, IT): “NGR/Vax/01: Spontaneous Clinical Trial”
Francesco De Rosa (Meldola, IT): “AbsIDe: tricks and tips for getting approved a non-sponsored clinical study with advanced therapy medicinal products in Italy”

Paola Queirolo (Genoa, IT): "Braf inhibitors beyond progression in melanoma: the BEYPRO1 study"

Ester Simeone (Naples, IT): “Vemurafenib plus PEG-interferon in advanced melanoma patients: the VEMUPLINT study”

Roberto Camerini (Rome, IT): “Non-profit studies and NIBIT Foundation”

**Abstracts selected for oral presentation**

18:50 Filippo Bellati (Rome, IT): “Preliminary results of a triple peptide escalating dose vaccination phase I/II clinical trial as consolidation treatment in women affected by ovarian cancer”

19:05 Serena Pellegatta (Milan, IT): “Combination of radiotherapy and chemotherapy with dendritic cell immunotherapy in glioblastoma patients induce NK and NKT cell but not CD8 T lymphocytes responses”

20:00 Social dinner

**Saturday, October 19**

**Session 7: Immunologic aspects of target therapy**
*Chairs:* Paola Allavena (Milan, IT) and Soldano Ferrone (Boston, USA)

9:00 Paola Allavena (Milan, IT): “Inflammation during target therapy”

9:25 Chiara Castelli (Milan, IT): “Immune modulation induced by targeted therapies in solid tumors: potential role in disease control and drug resistance”

9:50 Soldano Ferrone (Boston, USA): “Why it makes sense to use the BRAF inhibitor- IFNα combination for the treatment of melanoma with mutated active BRAF”

**Abstract selected for oral presentation**
10:15 Luigi Aurisicchio (Rome, IT): “A Novel Minigene Scaffold for Cancer Vaccine Applications”
10:30 Antonella Sistigu (Rome, IT): ”Cancer chemotherapy and viral mimicry”
10:45 Coffee break

Session 8: Prognostic and predictive biomarkers in bio-immunotherapy
Chairs: Enrico Proietti (Rome, IT) and Francesco M. Marincola (Doha, Q)
11:15 Keynote Lecture: Francesco M. Marincola (Doha, Q): “The continuum of immune surveillance”
11:45 Duccio Cavalieri (Trento, IT): “Systems biology approaches to DC based melanoma immunotherapy”
12:35 Graham Pawelec (Tubingen, DE): “Correlation between antigen-specific T cells and survival in melanoma”
13:00 Harpreet Singh (Tubingen, DE): “Actively personalized peptide vaccines for cancer therapy”

Abstract selected for oral presentation
13:25 Gilberto Filaci (Genoa, IT): “CD8+CD28-CD127loCD39+ Treg: a new T cell subset exclusively circulating in the peripheral blood of cancer patients”

13:40 Philogen and NIBIT Foundation Luncheon Satellite Symposium: Immunoconjugated monoclonal antibodies
Chairs: Massimo Di Nicola (Milan, IT) and Massimo Guidoboni (Meldola, IT)

Pier Adelchi Ruffini (Siena, IT): “Armed antibodies for cancer therapy: developments in solid tumors”
Mario Santinami (Milan, IT): “Isolated limb perfusion with armed antibodies in melanoma”

Riccardo Danielli (Siena, IT): “Intralesional armed antibodies in melanoma”

15:00  NIBIT AWARDS ASSIGNMENT

15:15  Adjourn